PharmaEngine, Inc. (4162.TWO)

94.90 +1.20 (+1.28%) At close: 01:30PM CST

PharmaEngine, Inc.

10 Minsheng East Road
11th Floor Sec. 3
Taipei 104
Taiwan
886 2 2515 8228
https://www.pharmaengine.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Hong-Ren Wang Ph.D.	President & CEO	N/A	N/A	N/A
Jose Hsieh	Senior Manager of Accounting	N/A	N/A	N/A
Mr. Chi-Hsing Chang	Vice President of Corporate Development	4.02M	N/A	N/A
Melody Lin	Director of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Corporate governance

PharmaEngine, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.